Skip to main content
SpringerLink
Log in

Identification of a LNCaP-Specific Binding Peptide Using Phage Display

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

To identify a LNCaP-specific peptide using a phage display library and evaluate its potential applications in targeted drug delivery.

Methods

Binding abilities of selected phages were evaluated by cell phage ELISA. The KYL peptide encoded by the most specific phage clone was synthesized, labeled with fluorescein, and assayed in various cell lines. A fusion peptide composed of the KYL peptide and a proapoptotic peptide D (KLAKLAK)2 was synthesized, and the cell death effect was evaluated on different cells. Moreover, the KYL peptide was conjugated to a cationic protein, protamine, to explore its potential application in siRNA delivery.

Results

One phage clone with a high binding affinity to LNCaP cells was identified. Cell phage ELISA and immunostaining demonstrated high specificity of this phage to LNCaP cells. The fluorescein-labeled KYL peptide exhibited higher binding to LNCaP cells in comparison to other cells. The fusion peptide composed of the KYL peptide and the proapoptotic peptide induced cell death in LNCaP cells, but not in PC-3 cells. The KYL peptide-protamine conjugate also efficiently delivered a fluorescein-labeled siRNA into LNCaP cells.

Conclusion

We identified a LNCaP-specific peptide and demonstrated its potential applications in targeted drug delivery to LNCaP cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

REFERENCES

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. Mabjeesh NJ, Zhong H, Simons JW. Gene therapy of prostate cancer: current and future directions. Endocr-Relat Cancer. 2002;9:115–39.

    Article  PubMed  CAS  Google Scholar 

  3. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 146:264–75.

  4. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE. 2009;4:e4171.

    Article  PubMed  Google Scholar 

  5. Yoneda Y, Steiniger SC, Capkova K, Mee JM, Liu Y, Kaufmann GF, et al. A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. Bioorg Med Chem Lett. 2008;18:1632–6.

    Article  PubMed  CAS  Google Scholar 

  6. Cesarone G, Edupuganti OP, Chen CP, Wickstrom E. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug Chem. 2007;18:1831–40.

    Article  PubMed  CAS  Google Scholar 

  7. Deutscher SL, Figueroa SD, Kumar SR. In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. J Labelled Comp Radiopharm. 2009;52:583–90.

    PubMed  CAS  Google Scholar 

  8. Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 49:1364–76.

  9. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 2006;66:9171–7.

    Article  PubMed  CAS  Google Scholar 

  10. Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 1999;59:2869–74.

    PubMed  CAS  Google Scholar 

  11. Yang W, Luo D, Wang S, Wang R, Chen R, Liu Y, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res. 2008;14:5494–502.

    Article  PubMed  CAS  Google Scholar 

  12. Wu C, Lo SL, Boulaire J, Hong ML, Beh HM, Leung DS, et al. A peptide-based carrier for intracellular delivery of proteins into malignant glial cells in vitro. J Control Release. 2008;130:140–5.

    Article  PubMed  CAS  Google Scholar 

  13. Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, et al. Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry. 2006;45:9434–44.

    Article  PubMed  CAS  Google Scholar 

  14. Jager S, Jahnke A, Wilmes T, Adebahr S, Vogtle FN, Delima-Hahn E, et al. Leukemia-targeting ligands isolated from phage-display peptide libraries. Leukemia. 2007;21:411–20.

    Article  PubMed  CAS  Google Scholar 

  15. Nishimura S, Takahashi S, Kamikatahira H, Kuroki Y, Jaalouk DE, O’Brien S, et al. Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells. J Biol Chem. 2008;283:11752–62.

    Article  PubMed  CAS  Google Scholar 

  16. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2003;4:393–403.

    Article  PubMed  CAS  Google Scholar 

  17. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 2006;8:772–80.

    Article  PubMed  CAS  Google Scholar 

  18. Shuklaand GS, Krag DN. Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens. J Drug Target. 2005;13:7–18.

    Article  Google Scholar 

  19. Smithand GP, Petrenko VA. Phage display. Chem Rev. 1997;97:391–410.

    Article  Google Scholar 

  20. Pero SC, Shukla GS, Armstrong AL, Peterson D, Fuller SP, Godin K, et al. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer. 2004;111:951–60.

    Article  PubMed  CAS  Google Scholar 

  21. Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem. 2002;21:287–96.

    Article  PubMed  CAS  Google Scholar 

  22. Sobeland RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines–part 2. J Urol. 2005;173:360–72.

    Article  Google Scholar 

  23. Sobeland RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol. 2005;173:342–59.

    Article  Google Scholar 

  24. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–11.

    PubMed  CAS  Google Scholar 

  25. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med. 2001;7:1249–53.

    Article  PubMed  CAS  Google Scholar 

  26. Liang S, Lin T, Ding J, Pan Y, Dang D, Guo C, et al. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med. 2006;84:764–73.

    Article  PubMed  CAS  Google Scholar 

  27. Bruccoleri RE, Haber E, Novotny J. Structure of antibody hypervariable loops reproduced by a conformational search algorithm. Nature. 1988;335:564–8.

    Article  PubMed  CAS  Google Scholar 

  28. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD. A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 2001;61:7709–12.

    PubMed  CAS  Google Scholar 

  29. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 2004;6:275–84.

    Article  PubMed  CAS  Google Scholar 

  30. Bruckheimer E, Harvie P, Orthel J, Dutzar B, Furstoss K, Mebel E, et al. In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma. Cancer Gene Ther. 2004;11:128–34.

    Article  PubMed  CAS  Google Scholar 

  31. Zhang JS, Li S, Huang L. Cationic liposome-protamine-DNA complexes for gene delivery. Meth Enzymol. 2003;373:332–42.

    Article  PubMed  CAS  Google Scholar 

  32. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–17.

    Article  PubMed  CAS  Google Scholar 

  33. Dinauer N, Lochmann D, Demirhan I, Bouazzaoui A, Zimmer A, Chandra A, et al. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J Control Release. 2004;96:497–507.

    Article  PubMed  CAS  Google Scholar 

  34. Mannervik B, Axelsson K, Sundewall AC, Holmgren A. Relative contributions of thioltransferase-and thioredoxin-dependent systems in reduction of low-molecular-mass and protein disulphides. Biochem J. 1983;213:519–23.

    PubMed  CAS  Google Scholar 

  35. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.

    PubMed  CAS  Google Scholar 

  36. McNamara 2nd JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24:1005–15.

    Article  PubMed  CAS  Google Scholar 

  37. Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, et al. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate. 2009;69:1077–90.

    Article  PubMed  CAS  Google Scholar 

  38. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032–8.

    Article  PubMed  CAS  Google Scholar 

  39. Sithanandam G, Fornwald LW, Fields J, Anderson LM. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene. 2005;24:1847–59.

    Article  PubMed  CAS  Google Scholar 

  40. Liu TG, Yin JQ, Shang BY, Min Z, He HW, Jiang JM, et al. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther. 2004;11:748–56.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

This work was supported by awards from National Cancer Institute (NCI), NIH (1R21CA143683-01) and National Institute of Alcohol Abuse and Alcoholism (NIAAA), NIH (1R21AA017960-01A1). We also would like to express thanks for the financial support from a start-up package at the University of Missouri-Kansas City.

Author information

Authors and Affiliations

  1. Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, Missouri, 64108, USA

    Bin Qin, Wanyi Tai, Ravi S. Shukla & Kun Cheng

Authors
  1. Bin Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wanyi Tai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ravi S. Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kun Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kun Cheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qin, B., Tai, W., Shukla, R.S. et al. Identification of a LNCaP-Specific Binding Peptide Using Phage Display. Pharm Res 28, 2422–2434 (2011). https://doi.org/10.1007/s11095-011-0469-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-011-0469-7

KEY WORDS

Search

Navigation